CARIBOU BIOSCIENCES INC. - COMMON STOCK

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

09 May 2023 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

08 May 2023 06:00:24 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 May 2023 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

17 Apr 2023 10:30:00 By Nasdaq GlobeNewswire

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

04 Apr 2023 05:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients

29 Mar 2023 05:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces Dosing of First Patient in the CaMMouflage Phase 1 Trial of CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

29 Mar 2023 05:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

09 Mar 2023 14:09:03 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

08 Mar 2023 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

01 Feb 2023 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

12 Dec 2022 05:01:00 By Nasdaq GlobeNewswire

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

12 Dec 2022 05:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

29 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

21 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

08 Nov 2022 13:00:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

07 Nov 2022 13:05:00 By Nasdaq GlobeNewswire

Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting

03 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022

18 Oct 2022 06:00:02 By Nasdaq GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

31 Aug 2022 13:05:00 By Nasdaq GlobeNewswire